Apr. 14 at 12:41 PM
$SLS MUST READ: The year-long "Cancer Calculus" investigation was a year-long investigation ( 124 journalists 48 newsrooms 37 countries. It's the ultimate
$SLS bull case.
It exposes
$MRK 's DESPERATION & patent games (1,212 patent applications) designed to keep prices high.
Merck needs
$SLS and fresh PATENTS to survive—or
$LLY or
$PFE will buy
$SLS to end
$MRK $31B in revenue.
A buyer like
$LLY or
$PFE could create a NEW Super-Drug patent by COMBINING
$SLS proprietary assets with GENERIC Keytruda in 2028 LEGALLY BLOCKING generic rivals from the BEST cocktails.
Trump & RFK Jr. want cost-effective cures. Vaccines like GPS are the answer.
With
$SLS- 009 targeting 20+ mutations where blockbusters fail, the urgency is at an all-time high. A bidding war is the only logical conclusion.
A
$31B valuation for
$SLS (matching Keytruda's annual haul) puts the stock at
$172.67/share.
Spending
$31B to protect a
$300B revenue stream over 10 years is "SMART as F*CK" https://www.icij.org/investigations/cancer-calculus/merck-keytruda-cancer-drug-price/
